Eli Lilly’s weight loss drug Zepbound has shown significant benefits in patients with a common type of heart failure and obesity, as per the late-stage trial data released by the company. The findings reveal that Zepbound, along with other popular GLP-1 drugs, offers health advantages beyond weight loss promotion and blood sugar regulation. The study